Dr. Jay Michael Huber, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 10024 Se 240th St Ste 220, Kent, WA 98031 Phone: 532-852-5440 Fax: 253-852-0272 |
Dan Nguyen, OD Optometrist Medicare: Medicare Enrolled Practice Location: 10024 Se 240th St Ste 220, Kent, WA 98031 Phone: 253-852-5440 |
Lewis S Lim And Associates Od Ps Optometrist Medicare: Medicare Enrolled Practice Location: 10024 Se 240th St, Ste 220, Kent, WA 98031 Phone: 253-852-5440 Fax: 253-852-0272 |
Edward Henry Kosnoski, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 10002 Se 240th St, Kent, WA 98031 Phone: 253-852-2020 Fax: 253-854-2020 |
Vladimir Stovbyr, OD Optometrist Medicare: Medicare Enrolled Practice Location: 10024 Se 240th St, Suite 220, Kent, WA 98031 Phone: 253-852-5440 Fax: 253-852-0272 |
Edward Michael Kosnoski Optometrist Medicare: Accepting Medicare Assignments Practice Location: 10002 Se 240th St, Kent, WA 98031 Phone: 253-852-2020 Fax: 253-854-2020 |
News Archive
A protein known for helping cells withstand stress may also act as a switch that triggers free-swimming Schistosoma larvae to begin penetrating the skin and transforming into the parasitic flatworms that burden more than 240 million people worldwide with schistosomiasis.
Today, the U.S. Food and Drug Administration took new steps as part of its broader efforts to address the opioid crisis by approving the final Opioid Analgesic Risk Evaluation and Mitigation Strategy.
Young people who combine alcohol with caffeine-laden energy drinks can end up drinking more than they intended to, finds a new study in the Journal of Adolescent Health.
A treatment derived from human embryonic stem cells improves mobility in rats with spinal cord injuries, providing the first physical evidence that the therapeutic use of these cells can help restore motor skills lost from acute spinal cord tissue damage.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
› Verified 5 days ago